Investigating how the end of SARS-CoV-2 RNA affects COVID-19 severity in obese individuals

The Untranslated 3'End of SARS-CoV-2 RNA as a Determinant of Obesity-Accelerated Infectivity

NIH-funded research Cleveland Clinic Lerner Com-Cwru · NIH-10689137

This study is looking at how being obese might affect how easily the COVID-19 virus can infect people, and it hopes to find new ways to help treat those who are at greater risk because of their weight.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCleveland Clinic Lerner Com-Cwru NIH-funded
Lab location1 site (Cleveland, United States)
Project IDNIH-10689137 on NIH RePORTER

What this research studies

This research focuses on understanding the relationship between obesity and the infectivity of SARS-CoV-2, the virus responsible for COVID-19. It aims to explore how the untranslated 3' end of the virus's RNA may influence its ability to infect individuals, particularly those who are obese. By examining the molecular mechanisms involved, the study seeks to identify potential therapeutic targets that could lead to improved antiviral treatments for patients who are at higher risk due to obesity. The research employs advanced biological assays to analyze the interactions between viral RNA and host cellular machinery.

Who could benefit from this research

Good fit: Ideal candidates for this research are adults aged 21 and older who are obese and may be at increased risk for severe COVID-19.

Not a fit: Patients who are not obese or those who do not have a risk of COVID-19 infection may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to the development of new antiviral therapies specifically tailored for obese patients, improving their treatment outcomes for COVID-19.

How similar studies have performed: While the specific focus on the 3' end of SARS-CoV-2 RNA in relation to obesity is novel, similar research has shown that understanding viral mechanisms can lead to successful therapeutic advancements.

Where this research is happening

Cleveland, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.